ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.
Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.
The user has been using minoxidil, microneedling, and finasteride for hair loss without improvement and is considering tretinoin, but concerns about shedding persist. Another user suggests trying dutasteride instead of finasteride, as both tretinoin and microneedling can irritate the skin.
The conversation is about choosing effective hair loss treatments, specifically discussing RU58841, 5% minoxidil, copper peptides, microneedling, finasteride, dutasteride, and Tretinoin. The user seeks advice on the best topical treatments and prefers to use only 1-2 products.
RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
Combining minoxidil with tretinoin appears to enhance hair growth for some users, with several reporting better results than using minoxidil alone. Some users also incorporate other treatments like dutasteride, latanoprost, and microneedling for improved outcomes.
The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.
The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
People are discussing using tretinoin gel with minoxidil to improve hair growth, especially for those who didn't respond to minoxidil alone. They apply a mix of tretinoin gel and minoxidil to the scalp, which is said to be more effective than minoxidil by itself.
The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
RU58841 users discuss increasing dosage for better hair regrowth, with some considering adding minoxidil and finasteride. Users report mixed results, with some experiencing side effects at higher doses.
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.
Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.
Combining tretinoin with minoxidil may improve absorption by exfoliating the scalp, but results vary. Users suggest starting with low frequency to avoid irritation, and some recommend additional treatments like finasteride or microneedling.
GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
The conversation discusses hair loss and treatments like finasteride, minoxidil, and ketoconazole shampoo. Users suggest scalp massages, warm showers, and other methods to address scalp tension and tight spots, with some mentioning the potential effects of medications like escitalopram and probiotics.
The efficacy of microneedling for hair regrowth as either a stand-alone therapy or adjunct to Minoxidil, and whether Tretinoin is a safer and more effective option. Replies include personal accounts from users who have had success with microneedling in combination with minoxidil and peptide serums, as well as considerations of technique, depth, and potential scarring.
The conversation is about using tretinoin to enhance the effects of minoxidil for hair loss, with suggestions to switch from finasteride to dutasteride or use RU58841 for better results. Concerns about tretinoin causing dry scalp and its potential impact on hair loss progression are also discussed.